MERS-CoV重組蛋白及病毒樣顆粒疫苗的研究
發(fā)布時(shí)間：2019-06-13 06:34
【摘要】：中東呼吸綜合征冠狀病毒(Middle East respiratory syndrome coronavirus, MERS-CoV)是2012年在中東地區(qū)發(fā)現(xiàn)的一種新型冠狀病毒,隨后該病毒從中東地區(qū)向外傳播。據(jù)世界衛(wèi)生組織(World Health Organization, WHO)報(bào)道,截止到2016年4月26日,全球共有27個(gè)國家1728例實(shí)驗(yàn)室確診病例,其中死亡624例,病死率高達(dá)36.1%。然而,目前尚無特異性藥物治療該病毒引起的感染。因此,丞待開發(fā)一種安全有效的疫苗預(yù)防或治療該病毒引起的疾病。MERS-CoV為包膜病毒,其包膜上的棘突蛋白(Spike, S)在介導(dǎo)病毒與宿主細(xì)胞膜結(jié)合以及病毒進(jìn)入細(xì)胞過程中發(fā)揮重要作用。S分為S1和S2兩個(gè)亞單位,前者介導(dǎo)病毒和易感細(xì)胞上的受體結(jié)合,后者在病毒包膜和宿主細(xì)胞膜融合中發(fā)揮作用。S1進(jìn)一步分為N端結(jié)構(gòu)域(N terminal domain, NTD)和C端的受體結(jié)合結(jié)構(gòu)域(Receptor binding domain, RBD)。RBD蛋白介導(dǎo)MERS-CoV與宿主細(xì)胞膜上的二肽基肽酶4(Dipeptidyl peptidase-4, DPP4)分子結(jié)合,富集中和性抗原表位,是MERS-CoV疫苗研發(fā)最重要的靶抗原。亞單位疫苗是預(yù)防病毒感染的重要手段,本文應(yīng)用重組RBD或NTD蛋白作為亞單位疫苗,先后在小鼠或恒河猴體內(nèi)檢測了其誘導(dǎo)的免疫應(yīng)答反應(yīng)和免疫保護(hù)效果。同時(shí)構(gòu)建了基于S蛋白的MERS-CoV嵌合型病毒樣顆粒(Virus like particles, VLPs)疫苗,并在小鼠體內(nèi)檢測了該VLPs的免疫原性。具體研究內(nèi)容及結(jié)果如下：1、重組RBD蛋白疫苗在小鼠體內(nèi)免疫效果研究重組RBD蛋白與不同佐劑(單獨(dú)鋁佐劑、鋁佐劑和CpG聯(lián)合、鋁佐劑和poly(I:C)聯(lián)合)經(jīng)肌肉注射,或與CpG和不完全弗氏佐劑(Incomplete Freund's adjuvant, IFA)聯(lián)合應(yīng)用經(jīng)皮下注射,可在BALB/c小鼠體內(nèi)誘導(dǎo)不同水平RBD特異性IgG抗體、中和抗體以及全身或局部細(xì)胞免疫應(yīng)答反應(yīng)。其中,重組RBD蛋白在鋁佐劑和CpG聯(lián)合作用下、經(jīng)肌肉注射可在小鼠體內(nèi)誘導(dǎo)最高水平的體液免疫應(yīng)答,且該免疫策略可誘導(dǎo)多種效應(yīng)性細(xì)胞因子的分泌。病毒攻擊實(shí)驗(yàn)表明,該策略可在小鼠體內(nèi)誘導(dǎo)有效的免疫保護(hù)反應(yīng),減輕MERS-CoV攻擊后小鼠肺臟和氣管組織的炎癥反應(yīng)。2、重組RBD蛋白疫苗在恒河猴體內(nèi)免疫效果研究高(200μg)、低劑量(50μg)重組RBD蛋白疫苗肌肉注射三次免疫恒河猴后,在其體內(nèi)誘導(dǎo)了強(qiáng)大而持久的體液免疫應(yīng)答(IgG抗體和中和抗體)。高劑量組重組RBD蛋白疫苗還誘發(fā)了有效的細(xì)胞免疫應(yīng)答。末次免疫后2w,恒河猴氣管內(nèi)接種6.5×107TCID50 MERS-CoV。結(jié)果發(fā)現(xiàn),與對(duì)照組相比免疫恒河猴肺部炎癥反應(yīng)較輕、肺臟和氣管病理改變輕微、肺組織MERS-CoV病毒載量和病毒滴度均較低。表明該重組RBD蛋白疫苗在恒河猴體內(nèi)誘導(dǎo)了有效的免疫保護(hù)反應(yīng)。3、重組NTD蛋白疫苗在小鼠體內(nèi)免疫效果研究重組NTD蛋白在鋁佐劑和CpG聯(lián)合作用下、經(jīng)肌肉注射三次免疫BALB/c小鼠。結(jié)果發(fā)現(xiàn),該重組NTD蛋白疫苗在小鼠體內(nèi)除誘導(dǎo)了中和抗體(水平略低于重組RBD蛋白疫苗)外,還誘導(dǎo)了高水平的細(xì)胞免疫應(yīng)答(強(qiáng)度顯著高于重組RBD蛋白疫苗)。該體液和細(xì)胞免疫應(yīng)答在小鼠體內(nèi)至少持續(xù)14w而無明顯下降。MERS-CoV攻擊后,病理結(jié)果示,雖然攻毒后的小鼠肺部出現(xiàn)炎癥改變,但較對(duì)照組明顯減輕,且該免疫保護(hù)水平與重組RBD蛋白疫苗相當(dāng)。4、VLPs疫苗的研制及免疫原性分析以禽流感病毒H5N1的基質(zhì)蛋白M1為骨架,在其表面嵌合MERS-CoV的S蛋白,應(yīng)用桿狀病毒表達(dá)系統(tǒng)在昆蟲細(xì)胞中包裝了MERS-CoV嵌合型VLPs。該VLPs在電鏡下與MERS-CoV相似,呈球形,直徑約100nm左右,具有典型的包膜以及“皇冠”樣外觀。該VLPs疫苗與鋁佐劑和CpG聯(lián)合應(yīng)用、經(jīng)肌肉注射免疫BALB/c小鼠后,可在其體內(nèi)誘導(dǎo)S蛋白特異性IgG抗體,且抗體滴度與滅活MERS-CoV疫苗相當(dāng)。此時(shí)血清亦檢測到中和抗體,但抗體滴度低于滅活MERS-CoV疫苗免疫組。以上研究表明,本研究成功構(gòu)建了有免疫原性的MERS-CoV嵌合型VLPs。綜上所述,本研究在小鼠或恒河猴體內(nèi)評(píng)價(jià)了重組RBD和NTD亞單位疫苗預(yù)防MERS-CoV感染的效果,結(jié)果表明該兩種亞單位疫苗均在動(dòng)物體內(nèi)誘導(dǎo)了有效的免疫應(yīng)答和明顯的免疫保護(hù)效果。應(yīng)用流感病毒M1為骨架,表面嵌合MERS-CoV S蛋白,成功構(gòu)建了嵌合型VLPs疫苗。該VLPs疫苗在小鼠體內(nèi)誘導(dǎo)了高水平的體液免疫應(yīng)答反應(yīng)。這些研究為MERS-CoV疫苗的研發(fā)以及人體應(yīng)用奠定了理論基礎(chǔ)。
[Abstract]:Middle East response syndrome coronavir (MERS-CoV) is a new coronavirus found in the Middle East in 2012, and the virus then spread out of the Middle East. According to the World Health Organization (WHO), as of 26 April 2016, there were 1728 laboratory-confirmed cases in 27 countries around the world, of which 624 died and the case fatality rate was as high as 36.1%. However, there is no specific drug currently being used to treat the infection caused by the virus. Therefore, a safe and effective vaccine is to be developed to prevent or treat the disease caused by the virus. MERS-CoV is a enveloped virus, and the spinous process protein (Spike, S) on the envelope plays an important role in mediating the binding of the virus to the host cell membrane and the entry of the virus into the cell. S is divided into S1 and S2 subunits, which mediate the binding of the receptors on the virus and the susceptible cells, which play a role in the fusion of the viral envelope and the host cell membrane. S1 is further divided into N-terminal domain (NTD) and C-terminal receptor binding domain (RBD). The RBD protein-mediated MERS-CoV binds to the dipeptidyl peptidase 4 (DPP4) on the host cell membrane to enrich the neutralizing antigen epitope and is the most important target antigen for the development of the MERS-CoV vaccine. Subunit vaccine is an important means for the prevention of viral infection. In this paper, the recombinant RBD or NTD protein is used as a subunit vaccine, and the induced immune response and the immune protective effect are detected in the mice or rhesus monkeys. The vaccine of the S-protein-based MERS-CoV chimeric virus-like particles (VLPs) was constructed, and the immunogenicity of the VLPs was also detected in the mice. The specific research contents and results are as follows:1. The recombinant RBD protein vaccine is used to study the immune effect of the recombinant RBD protein in the mouse, and the recombinant RBD protein and the different adjuvants (the separate aluminum adjuvant, the aluminum adjuvant and the CpG combination, the aluminum adjuvant and the poly (I: C)) are administered by intramuscular injection, Or in combination with CpG and incomplete Freund's aduviant, IFA), and can induce different levels of RBD-specific IgG antibodies, neutralizing antibodies, and systemic or local cellular immune response reactions in BALB/ c mice. In which, the recombinant RBD protein can induce the highest level of humoral immune response in the mouse body by intramuscular injection under the combination of the aluminum adjuvant and the CpG, and the immune strategy can induce the secretion of a plurality of effector cytokines. The virus attack experiment shows that the strategy can induce effective immune protection reaction in the mouse body, and the inflammation reaction of the lung and the trachea tissue of the mouse after the MERS-CoV attack is reduced. A strong and persistent humoral immune response (IgG antibody and neutralizing antibody) was induced in the body of the rhesus after the low-dose (50. mu.g) recombinant RBD protein vaccine was injected intramuscularly three times with the rhesus monkey. The high-dose recombinant RBD protein vaccine also induces an effective cellular immune response. 5-107 TCID50 MERS-CoV was inoculated in the trachea of the rhesus monkey after the last immunization. The results showed that, compared with the control group, the pulmonary inflammatory response of the rhesus monkey was light, the pathological changes of the lung and the trachea were mild, the lung tissue MERS-CoV viral load and the virus titer were both low. The results showed that the recombinant RBD protein vaccine induced an effective immune protective response in the rhesus monkey.3. The recombinant NTD protein vaccine was used to study the effect of the recombinant NTD protein in the mice. The BALB/ c mice were immunized with the three-time intramuscular injection of the recombinant NTD protein in the combination of aluminum adjuvant and CpG. As a result, the recombinant NTD protein vaccine induced a high level of cellular immune response (significantly higher in intensity than the recombinant RBD protein vaccine), in addition to the induction of neutralizing antibodies (slightly lower than the recombinant RBD protein vaccine) in the mice. The humoral and cellular immune response was at least 14 w in the body of the mouse without significant decrease. After the attack of MERS-CoV, the pathological results show that, although the inflammation of the lung of the mice after challenge is changed, the control group is obviously relieved, and the immune protection level is comparable to that of the recombinant RBD protein vaccine.4, the development and the immunogenicity analysis of the VLPs vaccine are based on the base protein M1 of the avian influenza virus H5N1, MERS-CoV chimeric VLPs were packaged in insect cells using a baculovirus expression system. The VLPs are similar to MERS-CoV under the electron microscope, have a spherical shape with a diameter of about 100 nm, and have a typical envelope and a "crown"-like appearance. The VLPs vaccine is used in combination with the aluminum adjuvant and the CpG. After the BALB/ c mice are immunized by intramuscular injection, the S-protein-specific IgG antibody can be induced in the BALB/ c mice, and the antibody titer is equivalent to the inactivated MERS-CoV vaccine. The serum also detected neutralizing antibodies, but the antibody titer was lower than that of the inactivated MERS-CoV vaccine. The above studies have shown that this study successfully constructed the immunogenic MERS-CoV chimeric VLPs. To sum up, the effect of recombinant RBD and NTD subunit vaccine on the prevention of MERS-CoV infection was evaluated in mice or rhesus monkeys, and the results showed that the two subunit vaccines induced an effective immune response and a clear immune protective effect in the animal. The chimeric VLPs vaccine was successfully constructed by using the influenza virus M1 as a skeleton and the surface-chimeric MERS-CoV S protein. The VLPs vaccine induced a high level of humoral immune response in mice. These studies have laid a theoretical foundation for the development of MERS-CoV vaccine and the application of human body.
【學(xué)位授予單位】：中國疾病預(yù)防控制中心
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R392
，
本文編號(hào)：2498314
[Abstract]:Middle East response syndrome coronavir (MERS-CoV) is a new coronavirus found in the Middle East in 2012, and the virus then spread out of the Middle East. According to the World Health Organization (WHO), as of 26 April 2016, there were 1728 laboratory-confirmed cases in 27 countries around the world, of which 624 died and the case fatality rate was as high as 36.1%. However, there is no specific drug currently being used to treat the infection caused by the virus. Therefore, a safe and effective vaccine is to be developed to prevent or treat the disease caused by the virus. MERS-CoV is a enveloped virus, and the spinous process protein (Spike, S) on the envelope plays an important role in mediating the binding of the virus to the host cell membrane and the entry of the virus into the cell. S is divided into S1 and S2 subunits, which mediate the binding of the receptors on the virus and the susceptible cells, which play a role in the fusion of the viral envelope and the host cell membrane. S1 is further divided into N-terminal domain (NTD) and C-terminal receptor binding domain (RBD). The RBD protein-mediated MERS-CoV binds to the dipeptidyl peptidase 4 (DPP4) on the host cell membrane to enrich the neutralizing antigen epitope and is the most important target antigen for the development of the MERS-CoV vaccine. Subunit vaccine is an important means for the prevention of viral infection. In this paper, the recombinant RBD or NTD protein is used as a subunit vaccine, and the induced immune response and the immune protective effect are detected in the mice or rhesus monkeys. The vaccine of the S-protein-based MERS-CoV chimeric virus-like particles (VLPs) was constructed, and the immunogenicity of the VLPs was also detected in the mice. The specific research contents and results are as follows:1. The recombinant RBD protein vaccine is used to study the immune effect of the recombinant RBD protein in the mouse, and the recombinant RBD protein and the different adjuvants (the separate aluminum adjuvant, the aluminum adjuvant and the CpG combination, the aluminum adjuvant and the poly (I: C)) are administered by intramuscular injection, Or in combination with CpG and incomplete Freund's aduviant, IFA), and can induce different levels of RBD-specific IgG antibodies, neutralizing antibodies, and systemic or local cellular immune response reactions in BALB/ c mice. In which, the recombinant RBD protein can induce the highest level of humoral immune response in the mouse body by intramuscular injection under the combination of the aluminum adjuvant and the CpG, and the immune strategy can induce the secretion of a plurality of effector cytokines. The virus attack experiment shows that the strategy can induce effective immune protection reaction in the mouse body, and the inflammation reaction of the lung and the trachea tissue of the mouse after the MERS-CoV attack is reduced. A strong and persistent humoral immune response (IgG antibody and neutralizing antibody) was induced in the body of the rhesus after the low-dose (50. mu.g) recombinant RBD protein vaccine was injected intramuscularly three times with the rhesus monkey. The high-dose recombinant RBD protein vaccine also induces an effective cellular immune response. 5-107 TCID50 MERS-CoV was inoculated in the trachea of the rhesus monkey after the last immunization. The results showed that, compared with the control group, the pulmonary inflammatory response of the rhesus monkey was light, the pathological changes of the lung and the trachea were mild, the lung tissue MERS-CoV viral load and the virus titer were both low. The results showed that the recombinant RBD protein vaccine induced an effective immune protective response in the rhesus monkey.3. The recombinant NTD protein vaccine was used to study the effect of the recombinant NTD protein in the mice. The BALB/ c mice were immunized with the three-time intramuscular injection of the recombinant NTD protein in the combination of aluminum adjuvant and CpG. As a result, the recombinant NTD protein vaccine induced a high level of cellular immune response (significantly higher in intensity than the recombinant RBD protein vaccine), in addition to the induction of neutralizing antibodies (slightly lower than the recombinant RBD protein vaccine) in the mice. The humoral and cellular immune response was at least 14 w in the body of the mouse without significant decrease. After the attack of MERS-CoV, the pathological results show that, although the inflammation of the lung of the mice after challenge is changed, the control group is obviously relieved, and the immune protection level is comparable to that of the recombinant RBD protein vaccine.4, the development and the immunogenicity analysis of the VLPs vaccine are based on the base protein M1 of the avian influenza virus H5N1, MERS-CoV chimeric VLPs were packaged in insect cells using a baculovirus expression system. The VLPs are similar to MERS-CoV under the electron microscope, have a spherical shape with a diameter of about 100 nm, and have a typical envelope and a "crown"-like appearance. The VLPs vaccine is used in combination with the aluminum adjuvant and the CpG. After the BALB/ c mice are immunized by intramuscular injection, the S-protein-specific IgG antibody can be induced in the BALB/ c mice, and the antibody titer is equivalent to the inactivated MERS-CoV vaccine. The serum also detected neutralizing antibodies, but the antibody titer was lower than that of the inactivated MERS-CoV vaccine. The above studies have shown that this study successfully constructed the immunogenic MERS-CoV chimeric VLPs. To sum up, the effect of recombinant RBD and NTD subunit vaccine on the prevention of MERS-CoV infection was evaluated in mice or rhesus monkeys, and the results showed that the two subunit vaccines induced an effective immune response and a clear immune protective effect in the animal. The chimeric VLPs vaccine was successfully constructed by using the influenza virus M1 as a skeleton and the surface-chimeric MERS-CoV S protein. The VLPs vaccine induced a high level of humoral immune response in mice. These studies have laid a theoretical foundation for the development of MERS-CoV vaccine and the application of human body.
【學(xué)位授予單位】：中國疾病預(yù)防控制中心
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R392
，
本文編號(hào)：2498314
本文鏈接：http://sikaile.net/yixuelunwen/jichuyixue/2498314.html
最近更新
教材專著
